INOZYME PHARMA, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 20[ ] by and between Inozyme Pharma, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”) [[Solely with respect to officers and directors that execute this form of indemnification agreement on or prior to the Company’s initial public offering:] and shall be effective as of the effectiveness of a Registration Statement on Form S-1 relating to the initial registration under the Securities Act of 1933, as amended, of shares of the Company’s common stock].
Inozyme Pharma, Inc. STOCK OPTION AGREEMENTStock Option Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
June 30, 2020 Steven Jungles Dear Steve:Employment Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This letter (the “Letter Agreement”) amends and restates the terms and conditions of your employment with Inozyme Pharma, Inc. (“Inozyme” or the “Company”), as initially set forth in the offer letter dated April 18, 2017 and as amended if applicable (the “Original Offer Letter”), and will be effective as of the date on which the registration statement relating to the Company’s initial public offering is effective (the “Effective Date”), provided that you remain employed by the Company as of the Effective Date. Until the Effective Date, the Original Offer Letter will remain in full force and effect and continue to govern your employment with the Company. This Letter Agreement contains the following terms:
Inozyme Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
INOZYME PHARMA, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), dated as of November 9, 2018, by and among INOZYME PHARMA, INC., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto (referred to hereinafter as the “Investors” and each individually as an “Investor”) amends and restates the Amended and Restated Investor Rights Agreement entered into as of April 13, 2017, by and among the Company and the Investors (defined therein) party thereto (the “Prior Agreement”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INTELLECTUAL PROPERTY ASSET...Intellectual Property Asset Purchase Agreement • July 20th, 2020 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS INTELLECTUAL PROPERTY ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 17, 2020 (the “Effective Date”) by and between Inozyme Pharma, Inc., a Delaware corporation with its principal office at 321 Summer Street, Floor 4, Boston, MA 02210 (the “Buyer”), on the one hand, and Alexion Pharmaceuticals, Inc., a Delaware corporation, with its principal office at 121 Seaport Boulevard, Boston, MA 02210 (the “Seller”, with Seller and Buyer each, individually, a “Party” and, collectively, the “Parties”), on the other hand.
